Innovation Pharmaceuticals Inc (IPIX)

[KMBJN]

Brilacidin was being considered as a possible adjuvant for vaccines, meaning something to provoke a stronger immune response to the actual vaccine, since some HDPs had promise as adjuvants. The paper mentioned this too.

HDPs, in particular human defensins, have been proposed as adjuvants for vaccine development.57, 58, 59

57 Park M.S., Kim, J.I., Lee, I., Park, S., Bae, J-Y., Park, M-S. (2018). Towards the Application of Human Defensins
at Antivirals. Biomol Ther(Seoul). 2018 May 1;26(3):242-254.
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5933891/
58 Kim, J., Yang, Y.L, Jang, S-H, Jang, Y-S. (2018). Human ß-defensin 2 plays a regulatory role in innate antiviral
immunity and is capable of potentiating the induction of antigen-specific immunity. Virol J. 2018; 15: 124.
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6083524/
59 Biragyn, A. (2005). Defensins—Non-antibiotic Use for Vaccine Development. Current Protein and Peptide
Science, Volume 6, Number 1, 2005, pp. 53-60(8).
https://www.eurekaselect.com/79061/article

One other thing we've talked about regarding whether brilacidin could work against other viruses was the need for the virus to have a net negative charge so the cationic brilacidin could puncture or otherwise inhibit its attachment and fusion to human cells. That was also briefly mentioned in the paper:

This mechanism of inhibition may be akin to that achieved by neutralizing antibodies that may interact with specific exposed epitopes on the surface of virions. It remains to be determined if the impact of brilacidin on viral membranes is driven by specific viral membrane compositions. Additional studies are planned.

And discussed here:

https://investorshub.advfn.com/boards/read_msg.aspx?message_id=155924953